www.bioreachpharma.com #PharmaIndustry #GLP1 #MetabolicHealth #IndiaPharma #GlobalHealthcare #PharmaceuticalExports #BioreachPharma Think, it is a structural shift, not growth.
Identifying Suitable Candidates Candidates suitable for semaglutide treatment typically include individuals with a BMI over 30, or those over 27 with at least one weight-related health issue like hypertension, type 2 diabetes, or high cholesterol
Unlike SGLT-2 inhibitors, semaglutide does not affect urinary glucose levels or create conditions that promote bacterial growth in the urinary tract
Co-treatment with morin hydrate suppresses this survival pathway by inhibiting the PARP-1/HMGB1/Beclin1 axis, enhancing apoptotic cell death and supporting morin-cisplatin combination therapy for liver cancer (5)
It's a frustrating, expensive, and entirely avoidable problem
Most forms of semaglutide are designed to last for a full week, which is why its given as a once-weekly injection